A new clinical study funded by non-profit organisation JDRF has revealed that a hybrid day-night closed-loop insulin delivery system (artificial pancreas) can control blood sugar levels better than sensor-augmented pump therapy in type 1 diabetes patients.

The study was conducted by the University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science and Addenbrooke’s Hospital.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It evaluated the capability of the closed-loop insulin delivery system in enabling blood sugar control in poorly controlled patients when compared to sensor-augmented pump therapy.

“Based on the findings, the researchers concluded that day-and-night hybrid closed-loop insulin delivery improves glycaemic control.”

Results showed that the proportion of time that glucose was in target range between 3·9 and 10mmol/l was significantly higher in the closed-loop group compared to sensor pump arm.

Also, subjects treated with the closed-loop systems experienced higher reductions in glycated haemoglobin (HbA1c) levels.

Sensor-augmented pump therapy involves a combination of an insulin pump with a continuous glucose monitoring sensor. The sensor transmits glucose readings to the person wearing the device, who will make all insulin-dosing decisions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, closed-loop insulin delivery systems combine continuous glucose monitoring with an insulin pump and an algorithm that enables automated insulin delivery.

During the study, the researchers treated a total of 86 patients characterised by sub-optimal blood sugar control with a sensor-augmented pump or the closed-loop therapy.

Based on the findings, the researchers concluded that day-and-night hybrid closed-loop insulin delivery improves glycaemic control.

A statement from the team read: “The use of day-and-night hybrid closed-loop insulin delivery improves glycaemic control while reducing the risk of hypoglycaemia in adults, adolescents and children with type 1 diabetes compared to conventional pump therapy or sensor-augmented pump therapy.

“Results from our study together with those from previous studies support the adoption of closed-loop technology in clinical practice across all age groups.”